Global On-body Injectors Supply, Demand and Key Producers, 2026-2032
Description
The global On-body Injectors market size is expected to reach $ 600 million by 2032, rising at a market growth of 16.2% CAGR during the forecast period (2026-2032).
On-body injectors, also known as on-body delivery systems (OBDS), are medical devices designed to deliver a controlled dose of medication or therapeutic substances subcutaneously (under the skin) over a specified period. These devices are typically worn on the body and are used to administer various treatments, including medications, hormones, and biologics. On-body injectors offer several advantages, including increased patient convenience, improved medication adherence, and the ability to deliver complex therapies. The scope of this report is non-insulin On-body injectors.
In 2024, the global sales ofnon-insulin on-body injectorsreached approximately5 million units, with an average market price of$35 per unit.
North America is currently the largest market for on-body injectors, driven by high healthcare spending, early adoption of advanced drug delivery technologies, and a strong presence of key players such as Amgen (with its Neulasta® Onpro® kit). The United States leads in the development and approval of wearable drug delivery systems, especially for chronic conditions like cancer and autoimmune diseases. Growing demand for home-based treatment and reduced hospital visits post-COVID-19 has further accelerated market expansion.
Europe is a strong and steadily growing market for on-body injectors, supported by rising prevalence of chronic diseases, aging populations, and robust healthcare infrastructure. Countries such as Germany, the UK, and France are key adopters, with regulatory support for patient-centric drug delivery systems. The focus on reducing hospital burden and improving patient compliance is encouraging healthcare providers to adopt wearable injectors, particularly for biologics and long-term therapies.
Asia-Pacific is the fastest-growing region for on-body injectors, driven by increasing healthcare awareness, expanding middle-class populations, and rising chronic disease incidence. Countries like China, Japan, and South Korea are investing heavily in digital health and self-administered therapies.
This report studies the global On-body Injectors production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for On-body Injectors and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of On-body Injectors that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global On-body Injectors total production and demand, 2021-2032, (K Units)
Global On-body Injectors total production value, 2021-2032, (USD Million)
Global On-body Injectors production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global On-body Injectors consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: On-body Injectors domestic production, consumption, key domestic manufacturers and share
Global On-body Injectors production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global On-body Injectors production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global On-body Injectors production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global On-body Injectors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include West Pharmaceutical Services, Insulet, Gerresheimer, United Therapeutics, CC Bio, BD, Ypsomed, Enable Injections, Nemera, Stevanato Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World On-body Injectors market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global On-body Injectors Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global On-body Injectors Market, Segmentation by Type:
Electronic Injectors
Mechanical Injectors
Global On-body Injectors Market, Segmentation by Application:
Immuno-oncology
Cardiovascular Diseases
Neurological Diseases
Others
Companies Profiled:
West Pharmaceutical Services
Insulet
Gerresheimer
United Therapeutics
CC Bio
BD
Ypsomed
Enable Injections
Nemera
Stevanato Group
Sonceboz
Lohmann Therapie-Systeme
Elcam Drug Delivery Devices (E3D)
MicroMED
Altek Medical
Key Questions Answered:
1. How big is the global On-body Injectors market?
2. What is the demand of the global On-body Injectors market?
3. What is the year over year growth of the global On-body Injectors market?
4. What is the production and production value of the global On-body Injectors market?
5. Who are the key producers in the global On-body Injectors market?
6. What are the growth factors driving the market demand?
On-body injectors, also known as on-body delivery systems (OBDS), are medical devices designed to deliver a controlled dose of medication or therapeutic substances subcutaneously (under the skin) over a specified period. These devices are typically worn on the body and are used to administer various treatments, including medications, hormones, and biologics. On-body injectors offer several advantages, including increased patient convenience, improved medication adherence, and the ability to deliver complex therapies. The scope of this report is non-insulin On-body injectors.
In 2024, the global sales ofnon-insulin on-body injectorsreached approximately5 million units, with an average market price of$35 per unit.
North America is currently the largest market for on-body injectors, driven by high healthcare spending, early adoption of advanced drug delivery technologies, and a strong presence of key players such as Amgen (with its Neulasta® Onpro® kit). The United States leads in the development and approval of wearable drug delivery systems, especially for chronic conditions like cancer and autoimmune diseases. Growing demand for home-based treatment and reduced hospital visits post-COVID-19 has further accelerated market expansion.
Europe is a strong and steadily growing market for on-body injectors, supported by rising prevalence of chronic diseases, aging populations, and robust healthcare infrastructure. Countries such as Germany, the UK, and France are key adopters, with regulatory support for patient-centric drug delivery systems. The focus on reducing hospital burden and improving patient compliance is encouraging healthcare providers to adopt wearable injectors, particularly for biologics and long-term therapies.
Asia-Pacific is the fastest-growing region for on-body injectors, driven by increasing healthcare awareness, expanding middle-class populations, and rising chronic disease incidence. Countries like China, Japan, and South Korea are investing heavily in digital health and self-administered therapies.
This report studies the global On-body Injectors production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for On-body Injectors and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of On-body Injectors that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global On-body Injectors total production and demand, 2021-2032, (K Units)
Global On-body Injectors total production value, 2021-2032, (USD Million)
Global On-body Injectors production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global On-body Injectors consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: On-body Injectors domestic production, consumption, key domestic manufacturers and share
Global On-body Injectors production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global On-body Injectors production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global On-body Injectors production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global On-body Injectors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include West Pharmaceutical Services, Insulet, Gerresheimer, United Therapeutics, CC Bio, BD, Ypsomed, Enable Injections, Nemera, Stevanato Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World On-body Injectors market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global On-body Injectors Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global On-body Injectors Market, Segmentation by Type:
Electronic Injectors
Mechanical Injectors
Global On-body Injectors Market, Segmentation by Application:
Immuno-oncology
Cardiovascular Diseases
Neurological Diseases
Others
Companies Profiled:
West Pharmaceutical Services
Insulet
Gerresheimer
United Therapeutics
CC Bio
BD
Ypsomed
Enable Injections
Nemera
Stevanato Group
Sonceboz
Lohmann Therapie-Systeme
Elcam Drug Delivery Devices (E3D)
MicroMED
Altek Medical
Key Questions Answered:
1. How big is the global On-body Injectors market?
2. What is the demand of the global On-body Injectors market?
3. What is the year over year growth of the global On-body Injectors market?
4. What is the production and production value of the global On-body Injectors market?
5. Who are the key producers in the global On-body Injectors market?
6. What are the growth factors driving the market demand?
Table of Contents
125 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
